UCB 📈 UCB SA - Overview

UCB SA is a biopharmaceutical company that specializes in developing and commercializing innovative treatments for patients with neurology and immunology diseases globally. The company's product portfolio includes a range of therapies, such as Cimzia, which is used to treat inflammatory TNF mediated diseases, including ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, and rheumatoid arthritis. Additionally, UCB SA offers a suite of epilepsy treatments, including Vimpat, Keppra, and Briviact, as well as Neupro for Parkinson's disease and restless legs syndrome.

The company's pipeline also features a number of promising treatments, including Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters, and Evenity, which is used to treat osteoporosis in postmenopausal women. UCB SA has also developed Bimzelx for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, and Fintepla for the treatment of Dravet syndrome. Furthermore, the company is investing in research and development for a range of new treatments, including rozanolixizumab and Zilbrisq for myasthenia gravis, dapirolizumab pegol for systemic lupus erythematosus, and fenfluramine for CDKL5 deficiency disorder.

UCB SA has established strategic partnerships with several major pharmaceutical companies, including Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka, to collaborate on the development and commercialization of new treatments. The company also engages in contract manufacturing activities, leveraging its expertise and capabilities to support the production of pharmaceuticals for other companies. With a history dating back to 1925, UCB SA is headquartered in Brussels, Belgium, and is listed on the stock exchange with the ISIN code BE0003739530, classified as a common stock in the pharmaceuticals sub-industry.

As a global biopharmaceutical company, UCB SA is committed to delivering innovative solutions that address the complex needs of patients with neurology and immunology diseases. With a strong focus on research and development, the company is continually investing in new treatments and technologies to improve patient outcomes and enhance quality of life. Through its partnerships and collaborations, UCB SA is able to leverage its expertise and resources to drive growth and expansion, while also contributing to the advancement of the pharmaceutical industry as a whole.